SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application

Core Viewpoint - SOPHiA GENETICS has launched a new Residual Acute Myeloid (RAM) Application to enhance measurable residual disease (MRD) testing, aimed at improving cancer monitoring and relapse prevention [1][2] Group 1: Product Features and Capabilities - The SOPHiA DDM™ RAM Solution utilizes next-generation sequencing (NGS) for MRD testing, capable of detecting one cancer cell among 10,000 cells, with a variant allele frequency (VAF) sensitivity down to 0.01% [2] - The application supports longitudinal variant monitoring, allowing visualization of the mutational landscape for each patient over time, and includes customizable reporting features for comprehensive MRD reports [8] - The solution will continuously improve its machine learning algorithms to provide accurate MRD results within four days [9] Group 2: Market Context and Importance - Acute Myeloid Leukemia (AML) accounts for about 1% of all cancers globally and has a high relapse rate, with over 50% of patients relapsing within three years of achieving complete remission [6] - MRD solutions are critical for informing post-remission therapy and detecting early relapse, serving as a primary endpoint in clinical trials to enhance patient outcomes [6][7] - The introduction of the RAM Solution addresses a significant unmet medical need in AML treatment, potentially transforming clinical research through improved tracking of individual mutations over time [7]